COMMUNIQUÉS West-GlobeNewswire

-
Celularity Inc. to Host Investor and Analyst Research & Development Day
22/04/2024 -
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
22/04/2024 -
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
22/04/2024 -
Excision BioTherapeutics Announces Oral Presentation of Preclinical HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24, 2024
22/04/2024 -
SS Innovations International Announces Q1 2024 Company Updates
22/04/2024 -
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
22/04/2024 -
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
22/04/2024 -
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
22/04/2024 -
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
22/04/2024 -
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
22/04/2024 -
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
22/04/2024 -
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
22/04/2024 -
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
22/04/2024 -
Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials
22/04/2024 -
BioCryst to Report First Quarter 2024 Financial Results on May 6
22/04/2024 -
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
22/04/2024 -
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
22/04/2024 -
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
22/04/2024 -
RadNet, Inc. Announces Date of its First Quarter 2024 Financial Results Conference Call
22/04/2024
Pages